Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 32.85 USD -2.46% Market Closed
Market Cap: 1.9B USD

Operating Margin
Stoke Therapeutics Inc

13.1%
Current
-742%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.1%
=
Operating Profit
26.8m
/
Revenue
205.6m

Operating Margin Across Competitors

No Stocks Found

Stoke Therapeutics Inc
Glance View

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

STOK Intrinsic Value
11.55 USD
Overvaluation 65%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.1%
=
Operating Profit
26.8m
/
Revenue
205.6m
What is the Operating Margin of Stoke Therapeutics Inc?

Based on Stoke Therapeutics Inc's most recent financial statements, the company has Operating Margin of 13.1%.

Back to Top